ClinicalTrials.gg
CompletedNCT01409122Updated Nov 9, 2012

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

A Phase 1 interventional study of 15 mg sodium nitrite inhalation solution and 90 mg sodium nitrite inhalation solution in Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Aires Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 56 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-09.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's listed conditions name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aires Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 56 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
122nd of 253
42 · median 40
Started
2011
with 19 others
Phase 1
32 of 312
2 open now
Registered
101st of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 122nd largest by enrollment of the 253 interventional ones that give a count, is one of 20 that started in 2011, is one of 32 in phase 1, and was the 101st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 56 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

This is a four-part study of the safety, tolerability, and PK profile of sodium nitrite inhalation solution (AIR001) of ascending multiple doses (Part A) and of escalating doses with steady-state sildenafil (Part B) to healthy male and female subjects, as well as assessment of the safety and tolerability of multiple doses of AIR001 to patients with pulmonary arterial hypertension (part C) with a single dose PK study of AIR001 utilizing three different nebulizers (Part D).

Read the detailed description

Pulmonary hypertension (PH) is an increase in the blood pressure (BP) in the small pulmonary vessels, arteries, veins or capillaries that results in progressive increases in right ventricular afterload, often leading to right ventricular failure and death. Pulmonary hypertension can result from a multitude of pathologies, including arterial etiologies, venous, chronic hypoxia related, thromboembolic, and other miscellaneous etiologies. In the recent Dana Point Classification, pulmonary arterial hypertension (PAH) was classified as Group 1. In Group 1 PAH, the pathologic lesion is localized to the small muscular pulmonary arteries, resulting in luminal narrowing and resistance to blood flow. Group 1 PAH includes idiopathic or sporadic PAH and heritable PAH which includes those with a family history of PAH. Associated PAH includes disease associated with connective tissue disease as well as PAH associated with congenital systemic to pulmonary shunts, portal hypertension, and human immunodeficiency virus (HIV) infection. Drug and toxin induced PAH is also in Group 1. Untreated, patients with PAH have an average life expectancy of 3 years, which declines to approximately 1 year if right heart failure is present.

Inhaled nitric oxide (NO) is a potent acute vasodilator. Its acute administration results in improved hemodynamics in the 10 to 15% of patients with PAH who demonstrate acute vasoreactivity. However, the usefulness of NO for chronic therapy is limited by the need for continuous inhalation. In patients who demonstrate vasoreactivity during an acute challenge with inhaled NO or a prostanoid challenge, therapy with calcium channel blockers has been demonstrated to result in improved symptoms and survival. In patients who do not demonstrate an acute vasodilator response, available therapies for PAH include prostanoids, endothelin receptor antagonists (ERA), and phosphodiesterase type-5 (PDE-5) inhibitors. However, the route and frequency of administration of the prostanoids, the hepatotoxicity of the ERAs, and concerns about the sustained efficacy of both the ERAs and PDE-5 inhibitors suggests that many patients with PAH could benefit from an effective therapy which offers ease of administration and a favorable toxicity profile.

Aires Pharmaceuticals, Inc. is developing a novel therapeutic, AIR001, for the treatment of PAH. The active ingredient in AIR001 is sodium nitrite, formulated in a buffered, pH-adjusted solution for nebulization. Preclinical data suggest that under the hypoxic, acidotic conditions present in the pulmonary hypertensive lung, inhaled sodium nitrite serves as a sustained release source of NO which will act as an acute pulmonary vasodilator. In addition, because decreased levels of NO have been shown to stimulate vascular remodeling, the increased NO resulting from nitrite inhalation is postulated to attenuate or reverse the pulmonary arterial remodeling process, resulting in both symptomatic improvement and pulmonary hemodynamic improvement in patients with PAH.

Preclinical experiments have shown that AIR001 by oral, IV, and inhalation routes of administration is effective in treating PAH induced by hypoxia or monocrotaline when administered as infrequently as once weekly at doses that generate plasma concentrations of approximately 1 to 10 uM and above. While the precise mechanism by which AIR001 exerts anti-hypertensive actions in PAH models remains to be elucidated, nitrite itself has been demonstrated to be metabolized to NO in animals and humans.

Single doses of AIR001 have been shown to be well tolerated in humans at dose levels that generate peak plasma concentrations (Cmax) in the target range established in preclinical models and no safety issues have been identified. AIR001 reduced PH induced by hypoxic gas inhalation in healthy volunteers at doses that are well tolerated. Preclinical and clinical data support further clinical investigation of inhaled AIR001 for the treatment of PAH. Before progressing to studies in patients with PAH, the safety and tolerability of multiple dose administration of AIR001 will be evaluated in Part A of the current study.

The PDE-5 inhibitor, sildenafil, is approved for use in patients with PAH and commonly used in the initial treatment for PAH. AIR001 is converted to NO, which increases cGMP dependent vasodilatation. Because PDE-5 inhibitors prevent the catabolism of cGMP by phosphodiesterase, it is possible that an exaggerated drug effect could be observed when AIR001 is administered to patients being treated with sildenafil. Therefore, combination safety and tolerability (in particular orthostatic effects) of escalating single doses of AIR001 will also be evaluated in combination with steady-state sildenafil in Part B of the study.

A cohort of patients with previously diagnosed PAH on stable background therapy will be assessed for safety and tolerability of multiple doses of AIR001 in Part C of the study.

Part D of the study will assess the PK, safety and tolerability of single dose AIR001 with each of three different nebulizers in a randomized crossover design.

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension

Browse trials for

Keywords

  • vasodilator
  • nitric oxide
  • sodium nitrite
  • sildenafil
  • PDE-5
  • pulmonary hypertension
  • pulmonary arterial hypertension
04

In context

Pulmonary Arterial Hypertension Reclassified

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

This study's enrollment of 42 is close to the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Aires Pharmaceuticals, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 56 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be informed of the nature of the study and is able to understand and has provided written informed voluntary consent
  • Be healthy males or females, of any race, at least 18 years of age or the legal age of consent (whichever is greater) and less than 56 years of age at the time of the first dose of study drug (or sildenafil)
  • Have a (BMI) >=18.0 and \<32.0 kg/m2 and weigh at least 50 kg
  • Be in good general health with no abnormalities based on the medical history, physical examination, clinical laboratory evaluations (hematology, clinical chemistry, urinalysis, methemoglobin), and 12-lead that, in the opinion of the Investigator, would affect subject safety
  • Agree to comply with the study procedures and restrictions

Exclusion criteria

Exclusion Criteria:

  • Any disease or condition that might affect drug absorption, metabolism, or excretion, or cardiovascular, ocular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease
  • Clinically significant illness (including lower respiratory tract infection) or clinically significant surgery within 4 weeks before the administration of study drug (or sildenafil)
  • Use of any commercially marketed mouthwash or oral rinse with agents other than tap water as well as tongue brushing or scraping from screening onwards through completion of study
  • Currently a smoker or has a past history of smoking (of >10 pack years)
  • History of bronchial asthma or sleep apnea
  • Evidence of restrictive or obstructive lung disease ( (FEV1)/Forced Vital Capacity (FVC) \<70%, FEV1 \<70% predicted, and/or FVC \<70% predicted)
  • Family history of primary PH
  • History of pulmonary embolism
  • Evidence of supine hypertension or hypotension (systolic BP >180 mmHg or \<90 mmHg and/or diastolic BP> 100 mmHg or \<50 mmHg) pre-dose [NOTE: BP measurements may be repeated twice, at least 10 minutes apart]
  • Orthostatic hypotension defined as a drop in systolic BP by >=20 mmHg or diastolic BP of >=10 mmHg at screening or predose or the development of significant postural symptoms (dizziness, lightheadedness, vertigo) when going from the supine to the standing position
  • Personal or family history of congenital or acquired methemoglobinemia
  • Personal or family history of RBC CYP B5 reductase deficiency
  • Personal or family history or any evidence of hemoglobinopathy
  • Known or suspected or allergic reaction to sodium nitrite, sodium nitrate, or saccharin
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency or any to receiving methylene blue
  • History of hypersensitivity or idiosyncratic reaction to drugs from multiple drug classes
  • If female, is pregnant or breast feeding, or has a positive pregnancy test result pre-dose
  • If a sexually active female, is not surgically sterile (defined as having had a hysterectomy, bilateral oophorectomy, or tubal ligation at least 6 months prior to screening) or (defined as amenorrhea for the past 2 years if \<50 years of age or for the past 1 year if \<=50 years or, if on hormone replacement therapy [HRT], documented follicle stimulating hormone [FSH] >30 IU/L before starting HRT), or does not agree to utilize two effective methods of consistently and as intended from screening until at least 4 weeks after the last dose of study drug. Subjects must use a barrier method (diaphragm with intravaginal spermicide, cervical cap with intravaginal spermicide, or partner using condoms plus use of intravaginal spermicide) in combination with at least one of the following methods of contraception:

    1. systemic hormonal contraceptive (oral, implant, injection, or patch)
    2. intrauterine device
    3. or male partner who has undergone a vasectomy at least 6 months prior to screening.
  • Unless approved by the Sponsor, chronic use of any systemic medications (with the exception of systemic hormonal contraceptives and vitamins taken at standard supplement doses); use of a drug therapy (including herbal preparations, e.g., St. John's wort) known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study drug (or sildenafil); use of prescription medication within 14 days before administration of study drug (or sildenafil) or over-the-counter [OTC] products (including natural products, vitamins) within 7 days before administration of study drug (or sildenafil). By exception, topical products without systemic absorption will be allowed. (NOTE: in particular, use of any PDE-5 inhibitor [e.g., sildenafil, tadalafil, vardenafil] is prohibited)
  • Current history or evidence of drug abuse, history of regular alcohol consumption exceeding 21 drinks/week for men and 14 drinks/week for women (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of screening or a positive screen for substances of abuse or alcohol at screening or pre-dose
  • Positive screen for surface antigen (HBsAg), antibody, or antibody
  • Receipt of an product or device, or participation in a drug research study within a period of 30 days (or 5 half-lives of the drug, whichever is longer) before the first dose of study drug (sildenafil)
  • Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of study drug (or sildenafil)
  • Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator, should preclude the subject's participation in this study

Part B Only:

  • Known or suspected hypersensitivity or allergic reaction to sildenafil or other therapeutics of similar chemical structure or any of the components of Revatio® tablets
  • Any medical condition that constitutes a contraindication or risk to taking sildenafil, including a history of hereditary degenerative retinal disorders such as retinitis pigmentosa
  • Ingestion of grapefruit or grapefruit juice within 72 hours before sildenafil administration
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part A Multiple Dose

    Ascending multiple dose administration (every 8 hours, \[Q8H\]) of AIR001 or placebo for 16 consecutive doses

    Drug: 15 mg sodium nitrite inhalation solution · Drug: 90 mg sodium nitrite inhalation solution · Drug: 45 mg sodium nitrite inhalation solution · Drug: 120 mg sodium nitrite inhalation solution

  • Experimental
    Part B Single Dose with Sildenafil

    Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)

    Drug: 25% MTD sodium nitrite inhalation solution

  • Experimental
    Part C, administration of AIR001 to patients with PAH

    Four doses of AIR001 will be administered via nebulization to patients with PAH.

    Drug: 90 mg sodium nitrite inhalation solution

  • Experimental
    Part D, device crossover study

    PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.

    Drug: 90 mg sodium nitrite inhalation solution

Interventions

  • Drug15 mg sodium nitrite inhalation solution

    15 mg sodium nitrite inhalation solution Q8H

  • Drug90 mg sodium nitrite inhalation solution

    90 mg sodium nitrite inhalation solution Q8H

  • Drug45 mg sodium nitrite inhalation solution

    45 mg sodium nitrite inhalation solution Q8H

  • Drug120 mg sodium nitrite inhalation solution

    120 mg sodium nitrite inhalation solution or placebo Q8H

  • Drug25% MTD sodium nitrite inhalation solution

    Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.

07

What researchers measure

Primary outcomes

  1. Safety and tolerability of ascending multiple dose AIR001 (Part A)

    To evaluate the safety and tolerability of ascending multiple dose administration (every 8 hours, \[Q8H\]) of AIR001 for 16 consecutive doses * Adverse Events * 12 lead ECG * Vital Signs (change in supine BP, Pulse Rate and change in orthostatic BP) * Venous Methemoglobin * Spirometry * Percutaneous Saturation of Oxygen and Methemoglobin concentrations * Plasma cGMP

    Time frame: 16 doses administered Q8H over 5 days

  2. Safety and tolerability of single escalating doses of AIR001 with sildenafil (Part B)

    To evaluate the safety and tolerability of single escalating doses of AIR001 when administered in combination with steady-state sildenafil administration. * Adverse Events * 12 lead ECG * Vital Signs (change in supine BP, Pulse Rate and change in orthostatic BP) * Venous Methemoglobin * Spirometry * Percutaneous Saturation of Oxygen and Methemoglobin concentrations * Plasma cGMP

    Time frame: 20 mg sildenafil Q8H for Days 1-6, single dose sodium nitrite inhalation solution over 10 min Days 4-6

  3. Composite PK for Plasma Nitrite and Nitrate(Part A)

    Cmax, tmax, AUC0-T, AUC0-inf, AUC%extrap, t½, CL/F, and Vz/F.

    Time frame: following 1st dose of AIR001 on Day 1 and final dose on Day 6

  4. Composite PK for Plasma Nitrite and Nitrate in the presence of steady state Sildenafil(Part B)

    : Cmax, tmax, AUC0-T, AUC0-inf, AUC%extrap, t½,CL/F, and Vz/F.

    Time frame: Following the third dose of AIR001 on Day 5,6,7

  5. Safety and tolerability of multiple doses of AIR001 administered to patients with PAH (PART C)

    To evaluate the safety and tolerability of multiple doses of AIR001 when administered in combination with steady-state background PAH medications in patients with PAH. * Adverse Events * 12 lead ECG * Vital Signs (change in supine BP, Pulse Rate and change in orthostatic BP) * Venous Methemoglobin * Spirometry * Percutaneous Saturation of Oxygen and Methemoglobin concentrations

    Time frame: Multiple doses of sodium nitrite inhalation solution over 10 min for a total of 4 doses

  6. Safety and tolerability of single doses of AIR001 administered to healthy subjects with each of three different nebulizers (PART D)

    To evaluate the safety and tolerability of single doses of AIR001 when administered in a randomized fashion with each of three different nebulizers in healthy volunteers. * Adverse Events * 12 lead ECG * Vital Signs (change in supine BP, Pulse Rate and change in orthostatic BP) * Venous Methemoglobin * Spirometry * Percutaneous Saturation of Oxygen and Methemoglobin concentrations

    Time frame: Multiple doses of sodium nitrite inhalation solution over 10 min for a total of 4 doses

  7. Composite PK for Plasma Nitrite and Nitrate(Part C)

    Cmax, tmax, AUC0-T, AUC0-inf, AUC%extrap, t½, CL/F, and Vz/F.

    Time frame: following 1st dose of AIR001 on Day 1 and final dose on Day 2

  8. Composite PK for Plasma Nitrite and Nitrate(Part D)

    Cmax, tmax, AUC0-T, AUC0-inf, AUC%extrap, t½, CL/F, and Vz/F.

    Time frame: following each dose of AIR001 with three different nebulizers

08

Study locations

1 site
  • PAREXEL International Early Phase Clinical Unit - Baltimore
    Baltimore, Maryland 21225, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2011
First posted
Aug 4, 2011
Start
Jul 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Nov 9, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01409122
Lead sponsor
Aires Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 4, 2011
Start date
Jul 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Nov 9, 2012

Study contacts

Azra Hussaini, MD
principal investigator · PAREXEL International - Baltimore

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion